Core Viewpoint - ChemoMetec has adjusted its revenue and EBITDA guidance for the financial year 2025/26 due to several market challenges, despite a strong competitive position in cell counting automation [1][2]. Group 1: Market Challenges - The North American market for cell and gene therapy has been impacted by government lockdowns and geopolitical uncertainties, leading to prolonged decision-making processes among customers [5]. - The implementation of automation in the production of cell and gene therapies has proven to be more time-consuming than anticipated, causing delays in validations and decisions [5]. - Increased interest in the XcytoMatic platform has resulted in a slowdown in sales of NC instruments and associated consumables [5]. Group 2: Financial Adjustments - Revenue is now expected to be in the range of DKK 490-520 million, a decrease from the previously announced DKK 565-580 million [2]. - EBITDA is projected to be between DKK 260-285 million, down from the earlier guidance of DKK 320-335 million [2]. Group 3: Competitive Position - ChemoMetec continues to see a growing number of automation projects and confirms that its XcytoMatic products remain attractive and competitive in the market [1]. - The upcoming introduction of the new software platform XM Octopus is expected to further strengthen ChemoMetec's market position [1].

Core Insights - ChemoMetec reported an 8% increase in revenue for Q1 2025/26, reaching DKK 124.6 million, with a 11% increase at constant exchange rates, driven by growth in sales of instruments, consumables, and services [1][8] - EBITDA for the first quarter rose to DKK 68.8 million, reflecting an 11% year-on-year increase, resulting in an EBITDA margin of 55% [2][21] Revenue Performance - Revenue increased from DKK 115.6 million in Q1 2024/25 to DKK 124.6 million in Q1 2025/26, marking an 8% growth [3][10] - Sales of instruments grew by 4% to DKK 40.7 million, while consumables and services saw increases of 12% and 4%, respectively [8][11] - The Life Science Research, Cell and Gene Therapy, and Bioprocessing (LCB) segment accounted for 94% of total revenue, with an 8% increase in this area [8][18] Product Development - Development of the XcytoMatic 50 (XM50) and the Sample Management System is progressing as planned, with positive customer feedback received at a major conference [5][6] - The XcytoMatic product line has seen significant sales growth, contributing positively to overall revenue [9][11] Geographic Revenue Breakdown - Revenue in the USA/Canada region grew by 4% to DKK 71.1 million, accounting for 57% of total Q1 revenue [13] - European revenue increased by 18% to DKK 42.9 million, driven by a 33% rise in consumables sales [14] - Revenue from the Rest of the World (RoW) remained stable at DKK 10.6 million, accounting for 9% of total revenue [15] Guidance and Future Outlook - The company maintains its full-year guidance for 2025/26, expecting revenue in the range of DKK 565-580 million and EBITDA between DKK 320-335 million [22]